Eli Lilly specifies guidance for this year's revenue
The USD 200m increase in the estimated revenue from products within Eli Lilly's core business, leads the US company to specify its guidance for the 2021 revenue. Now, the pharmaceutical company expects a revenue in the range of USD 26.8bn-27.4bn.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
On Tuesday, US pharmaceutical company Eli Lilly detailed its guidance for the company's revenue for 2021 in connection with the publication of the pharmaceutical company's Q2 report.